已收盘 08-01 16:00:00 美东时间
+0.070
+1.82%
Prothena Corp (NASDAQ:PRTA) will release its quarterly earnings report on Monda...
08-02 05:05
Myriad Genetics ( ($MYGN) ) just unveiled an announcement. On July 31, 2025, My...
07-31 21:48
Myriad Genetics (NASDAQ:MYGN) announced on Thursday it has closed a five-year senior secured term loan credit facility providing up to $200 million of capital from OrbiMed. The facility includes $125 ...
07-31 20:51
Illumina TruSight™ Oncology 500 v2 research assay is now available with built-in HRD biomarker detection, faster turnaround time, and lower tissue sample input Illumina's growing research an...
07-30 21:15
Salt Lake City, July 29, 2025: Myriad Genetics, a leader in molecular diagnostics and precision medicine, will host its 2Q 2025 earnings call on August 5 at 4:30pm ET. The event will feature a financial overview and business update. A live webcast will be available on investor.myriad.com, and participants can register via the provided link to join via telephone. An archived version will be accessible post-call. For more information, visit www.myr...
07-29 20:05
摩根大通美股分析师团队近日发表研报,筛选出了今年下半年“最具吸引力的结构性及战术性做空标的”。
07-15 15:14
Myriad Genetics has been certified as a "Great Place to Work" for the third consecutive year, with 84% of employees rating it highly. Employees highlight inclusive culture, resource groups, and support. The certification, based solely on employee feedback, reflects Myriad's commitment to fostering a connected, supportive workplace.
07-15 13:00
J.P. Morgan’s U.S. equity research analysts compiled their list of “most compelling structural and tactical short ideas” for the second half of the year. Below are the short ideas, followed by a quote...
07-14 22:39
原标题:数问生物完成近亿元C1轮融资,金创投领投 投资界(ID:pedaily2012)7月10日消息,数医学诊断服务提供商数问生物完成近亿元C1轮融资,本轮...
07-10 13:01
Myriad Genetics, Inc. announced the early access to its FirstGeneTM Multiple Prenatal Screen, which combines several genetic tests into one assay to assess fetal genetic risks, including chromosomal abnormalities, severe recessive diseases, and RhD compatibility, without requiring paternal samples. A large-scale clinical study with over 5,000 patients will evaluate its performance, achieving high sensitivity and specificity. The FirstGene screen ...
06-03 13:00